Earlier this week the US Treasury   to prevent tax inversions a tactic in which a US company buys another thats domiciled in an overseas country with a much lower tax rate The idea which has grown popular with drug and device makers is to generate a lower tax rate and also use cash parked outside the US in ways that also deflect some taxes We spoke with Robert Willens an independent tax advisor who tracks corporate tax maneuvers about the implications especially for two deals  AbbVies planned acquisition of Shire and Medtronics deal to buy Covidien